Skip to main content
Premium Trial:

Request an Annual Quote

Specialty Labs to Begin Selling Roche s AmpliChip CYP450 Test by End of Month

NEW YORK, Oct. 10 (GenomeWeb News) - Clinical reference lab Specialty Laboratories said today that it has signed an agreement to begin co-marketing Roche Diagnostics' AmpliChip CYP450 assay by the end of the month.

 

The AmpliChip CYP450, which is built upon the Affymetrix microarray platform, analyzes the cytochrome P450 2D6 and 2C19 genotypes to help determine the appropriate dosages of medications for a variety of conditions, including pain medication, cardiac disease, cancer, and depression.

 

David Weavil, CEO of Specialty Laboratories, said in a statement that the assay "can help determine whether a standard dose of a drug metabolized in a patient with a particular genotype would be appropriate, or whether it might cause significant or serious side effects, or even toxicity." The test can also "predict whether a standard dosing schedule of expensive medications would be cleared from a person's body so quickly that it does not achieve effective therapeutic levels," Weavil said.

 

Specialty said that it also plans to launch a marketing campaign "to educate clients about the test's value."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.